DV
Dividend Vision

APGE Stock — Apogee Therapeutics, Inc.

No longer trading. This fund has been liquidated; the figures below are frozen at its final trading day.

Apogee Therapeutics, Inc. (APGE)

Updated September 2, 2026.

Apogee Therapeutics develops biologic therapies for immunological and inflammatory diseases, with a pipeline of monoclonal antibodies and combination therapies targeting conditions including atopic dermatitis, asthma, and eosinophilic esophagitis, along with antibody engineering services. The company does not currently distribute to shareholders. This security appeals to those seeking exposure to early-stage biopharmaceutical development rather than income generation.

APGE key facts

Asset type
Stock
Asset class
Equity
Inception date
07/13/2023
Distribution frequency
None
Last close
$135.07 (stale; as of 2026-09-02)
Market cap
$10,223,142,912
Average volume
2,925,094
Beta
0.327
Payout ratio
0.0%
Forward P/E
-26.00
EPS
-$4.34

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.